Eledon Pharmaceuticals, Inc.
For the period ended Jun 18, 2026. Filed Jun 22, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jun 18, 2026 · Filed Jun 22, 2026
Use the contents to explore the available documents and sections.
ELDN$2.61+5.9%Stored close · as of Nov 6, 2026
Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Eledon Pharmaceuticals | |||
| Date: | June 22, 2026 | By: | /s/ David-Alexandre C. Gros, M.D. |
|---|---|---|---|
| Name: David-Alexandre C. Gros. M.D.Title: Chief Executive Officer | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.